Healthcare
Veradermics, Incorporated(MANE)
Live Price
Offline$93.87
+2.18% today
Window Change
+11.43%
Window
May 4, 2026 โ Jun 24, 2026
- Market Cap
- $3.77B
- Revenue Growth
- 0.0%
- EPS Growth
- -70.9%
- Dividend Yield
- 0.0%
Historical coverage is still filling in
This 1Y daily history view is currently sparse. Use it as directional context while we continue backfilling more history.
Coverage: 36 bars ยท May 4, 2026 โ Jun 24, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Veradermics, Incorporated (MANE) is a Healthcare stock with a market cap of $3.77B and listed on NYSE. The stock last traded around $93.87 and up 11.4% across the available one-year price window (May 4, 2026 โ Jun 24, 2026). Baseline metrics include revenue growth of 0.0%, EPS growth of -70.9%, a dividend yield of 0.0%. What stands out right now is revenue 0.0%, EPS -70.9%, free cash flow -75.3% with operating margin 0.0% and ROIC -49.0%. Overall, the current profile looks closer to a turnaround or cyclical reset than a generic broad-market placeholder. Stock Foundry combines MANE price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Sector Context
How this name stacks up against nearby peers on first-pass metrics.
Revenue Growth
Below sector median
0.0% vs +7.6% peer median
Operating Margin
Below sector median
0.0% vs +19.4% peer median
What Changed This Quarter
Latest report context and the signals most likely to have changed the story.
Latest report is on the board
2026 was reported on May 15, 2026, but the surprise data is still limited.
The operating picture looks softer than before
Revenue is at 0.0% and EPS is at -70.9%, with operating margin around 0.0%.
Benchmark Edge
MANE vs SPY, QQQ, and Sector ETFs
Normalized return, excess return, max drawdown, and calendar-year wins against the benchmarks investors actually use.
MANE
โ
Normalized return
SPY
--
S&P 500
Excess Return
--
Relative to SPY
MANE Max Drawdown
-21.32%
Trailing 1Y
SPY Max Drawdown
โ
Trailing 1Y
Calendar-Year Returns
Uses the longest available daily history for MANE and SPY.
Company Overview
Veradermics, Incorporated
New York Stock Exchange
Veradermics, Incorporated operates as a biopharmaceutical company focused on developing novel therapeutics for dermatologic and aesthetic conditions. The company develops treatments for Pattern Hair Loss affecting adults and children. The company's products include VDPHL01, an oral, non-hormonal treatment for men and women with PHL for chronic hair loss therapy. Additionally, it engages in the development of VDMN, a dissolvable microarray patch technology for immunotherapy of common warts; VDAA for the treatment of alopecia areata; and VDMC for the treatment of molluscum contagiosum. Its products are used for the treatment of androgenetic alopecia, common warts, molluscum contagiosum, alopecia areata, and atopic dermatitis. The company serves healthcare providers and clinicians treating dermatologic and aesthetic conditions in both adult and pediatric populations, as well as the broader medical and clinical research community involved in dermatology. Veradermics, Incorporated was founded in 2019 and is based in New Haven, Connecticut.
- Leadership
- Reid Waldman
- IPO Date
- Feb 4, 2026
- Employees
- 21
- Street Address
- 470 James Street
- Mailing
- New Haven, CT, 06513
- Region
- New Haven, CT, US
- Reporting Currency
- USD
- Investor Line
- (228) 372-3376
- Last Updated
- May 2, 2026
Key Fundamentals
Valuation, growth, profitability, and balance sheet signals.
Valuation
- P/E
- โ
- EV/EBITDA
- โ
- Price/Sales
- โ
- Price/Book
- 372.0
Growth
- Revenue
- 0.0%
- EPS
- -70.9%
- Free Cash Flow
- -75.3%
Profitability
- Gross Margin
- 0.0%
- Operating Margin
- 0.0%
- Net Margin
- 0.0%
- ROE
- -76.5%
- ROIC
- -49.0%
Balance Sheet
- Debt/Equity
- โ
- Current Ratio
- 11.77
Earnings Reports
Latest News
Official Releases
Company announcements and filings-style updates.
Next Step
Keep the research moving
After the overview, the strongest next step is usually chart context or a tighter compare set.